Alvotech plans to invest $250 million in the development and manufacture of a portfolio of biosimilar monoclonal antibodies. Alvotech began construction of a new 11,800-square-meter development and manufacturing facility, where it will produce its own developed biosimilars. Alvotech’s current biosimilar assets include undisclosed follow-on versions of leading monoclonal antibodies, which are expected to launch by 2018.   Alvotech, based Reykjavik, Iceland, is a sister company of the multin...